show episodes
 
P
Personalizing Treatment and Managing Patient Concerns
 
Drs. Bradley Monk and Robert Coleman examine practical issues to consider in managing toxicities associated with antiangiogenic agents: dealing with side effects of first-line versus palliative treatment, the possibility of dose reduction to alleviate toxicities, risk factors for catastrophic side effects such as RPLS and GI perforation, and whether patients with serious side effects can be re-treated when these events have resolved. They also address the role of sensitivity tests and molecu ...
 
U
Using Targeted Therapies in a Real-World Setting
 
In this engaging podcast, Drs. Bradley Monk and Robert Burger discuss important practical issues regarding the use of antiangiogenic therapy to treat epithelial ovarian cancer, including the possible value of targeted agents as maintenance therapy, the correct dosage and duration of targeted therapy, and the role of CA125 in determining tumor progression with a biologic agent
 
Loading …
show series
 
Today I will be discussing Mvasi, which is the first oncology biosimilar (to Avastin/bevacizumab) to be approved by the US Food and Drug Administration. Accompanying each episode is a downloadable slide deck and online module, which you can access at psomedia.com/NDA. Today’s slide deck is free and may be helpful to clinicians, medical writers ...…
 
Anti-VEGF Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Post-Hoc Analyses Lee M. Jampol, MD, Adam R. Glassman, MS, Neil M. Bressler, MD, John A. Wells, MD, Allison R. Ayala MS JAMA Ophthalmol. 2016;134(12):1429-1434. doi:10.1001/jamaophthalmol.2016.3698 Abstract Importance: Post-hoc analyses from DRCR.net randomized tri ...…
 
Webcast: Great Debates and Updates in GI Malignancies 2017
 
Webcast: Great Debates and Updates in GI Malignancies 2017
 
Drs. Ajay Kuriyan and Daniel Chao join Jay for a group discussion of two recent articles: one in Ophthalmology looking at diabetic retinopathy severity progression in the FAME study (link) and another in the American Journal of Ophthalmology examining outcomes of intravitreal bevacizumab for diabetic vitreous hemorrhage (link).…
 
Drs. Ajay Kuriyan and Daniel Chao join Jay for a group discussion of two recent articles: one in Ophthalmology looking at diabetic retinopathy severity progression in the FAME study (link) and another in the American Journal of Ophthalmology examining outcomes of intravitreal bevacizumab for diabetic vitreous hemorrhage (link).…
 
S
Straight From The Cutter's Mouth: A Retina Podcast
 
Dr. Jeffrey Heier Dr. Jeffrey Heier of Ophthalmic Consultants of Boston joins the show to discuss why he uses bevacizumab as his initial agent for various retinal conditions, the role of laser in his treatment of diabetic retinopathy, and more.
 
S
Straight From The Cutter's Mouth: A Retina Podcast
 
Dr. Jeffrey Heier Dr. Jeffrey Heier of Ophthalmic Consultants of Boston joins the show to discuss why he uses bevacizumab as his initial agent for various retinal conditions, the role of laser in his treatment of diabetic retinopathy, and more.
 
B
BioMed Radio - Washington University School of Medicine in St. Louis
 
A new study reveals that some eye specialists who receive money from pharmaceutical companies are more likely to use drugs promoted by those companies than similar drugs that are equally effective but less expensive. Although the data can�t confirm a cause and effect between money from industry and the prescribing habits of some physicians, res ...…
 
Bradley Monk, MD is a gynecologic oncologist and professor at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona. His main clinical interests include gynecologic malignancies and quality-of-life aspects of cancer care. He spoke with Oncology Data Advisor about the definition of recurrent ovar ...…
 
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.
 
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.By west@cancergrace.org (cancerGRACE - H. Jack West, MD).
 
G
GRACEcast ALL Subjects audio and video
 
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.By west@cancergrace.org (cancerGRACE - H. Jack West, MD).
 
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.By west@cancergrace.org (cancerGRACE - H. Jack West, MD).
 
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.By west@cancergrace.org (cancerGRACE - H. Jack West, MD).
 
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.
 
Drs. Ben Solomon, Leora Horn, & Jack West review trial result and implications of ECOG 1505 trial that showed no benefit to addition of Avastin (bevacizumab) to adjuvant chemotherapy for early stage NSCLC.By west@cancergrace.org (cancerGRACE - H. Jack West, MD).
 
Drs. Ben Solomon, Leora Horn, & Jack West review trial result and implications of ECOG 1505 trial that showed no benefit to addition of Avastin (bevacizumab) to adjuvant chemotherapy for early stage NSCLC.By west@cancergrace.org (cancerGRACE - H. Jack West, MD).
 
Drs. Ben Solomon, Leora Horn, & Jack West review trial result and implications of ECOG 1505 trial that showed no benefit to addition of Avastin (bevacizumab) to adjuvant chemotherapy for early stage NSCLC.
 
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.By west@cancergrace.org (cancerGRACE - H. Jack West, MD).
 
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.By west@cancergrace.org (cancerGRACE - H. Jack West, MD).
 
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.
 
Harry Bear discusses the use of adjuvant and neoadjuvant bevacizumab in the treatment of early breast cancer.
 
New Biological Insights and Recent Therapeutic Advances in the Management of Lung Cancer: A Clinical Investigator Think Tank | Video excerpts from a clinical investigator Think Tank featuring perspectives from Drs David P Carbone, Mark G Kris, Corey J Langer, Geoffrey R Oxnard, David R Spigel and Anne S Tsao on emerging data and recent therapeu ...…
 
A French study presented at ASCO 2015 showed a survival benefit with Avastin (bevacizumab) added to standard chemo, unlike a prior US study. The doctors discuss the influence of this trial and future potential benefits from immunotherapy in mesothelioma.By west@cancergrace.org (cancerGRACE - H. Jack West, MD).
 
A French study presented at ASCO 2015 showed a survival benefit with Avastin (bevacizumab) added to standard chemo, unlike a prior US study. The doctors discuss the influence of this trial and future potential benefits from immunotherapy in mesothelioma.
 
A French study presented at ASCO 2015 showed a survival benefit with Avastin (bevacizumab) added to standard chemo, unlike a prior US study. The doctors discuss the influence of this trial and future potential benefits from immunotherapy in mesothelioma.By west@cancergrace.org (cancerGRACE - H. Jack West, MD).
 
(February 23, 2015 - Insidermedicine) From Chicago - New research published in the NEJM finds that for the eye condition diabetic macular edema (DME), the drug aflibercept (Eylea) may be more effective than its alternatives. The researchers found that in DME patients with moderate visual impairment, 20/50 or worse, those receiving aflibercept h ...…
 
J
JAMA Ophthalmology Author Interviews: Covering research, science, & clinical practice in ophthalmology and vision science
 
Interview with Helen A. Mintz-Hittner, MD, author of Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment: A Randomized Clinical Trial
 
J
JAMA Ophthalmology Author Interviews: Covering research, science, & clinical practice in ophthalmology and vision science
 
Interview with Helen A. Mintz-Hittner, MD, author of Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment: A Randomized Clinical Trial
 
S
Specialty Journals Author Interviews: Research in medicine, science & clinical practice for physicians, researchers, clinicians
 
Interview with Helen A. Mintz-Hittner, MD, author of Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment: A Randomized Clinical Trial
 
(August 19, 2014 - Insidermedicine) From Texas - A new report published in Ophthalmology examines outcomes among children treated with bevacizumab for retinopathy of prematurity. Researchers studied over 130 infants with retinopathy of prematurity with a mean age of 2.5 years. Participants were randomized to either intravitreal bevacizumab inje ...…
 
Dr. Heather Wakelee of Stanford University Medical Center talks about how studies looking into Avastin (bevacizumab) for early stage lung cancer patients are progressing. February 2014.By west@cancergrace.org (cancerGRACE - H. Jack West, MD).
 
J
Journal of Clinical Oncology (JCO) Podcast
 
This podcast discusses the results of an analysis of the risk of severe gastrointestinal toxicity associated with the administration of bevacizumab to women with advanced ovarian cancer.By Maurie Markman.
 
Observations from the AURELIA trial evaluating bevacizumab combined with chemotherapy in platinum resistant recurrent ovarian cancer patients and results from Patient-Reported Outcomes.By Alexia Iasonos.
 
Dr. David Kerr reports on a plausible study suggesting a link between MMR-deficient colon tumors and response to bevacizumab in the adjuvant setting.
 
J
Journal of Clinical Oncology (JCO) Podcast
 
The AVAPERL trial reveals a significant improvement in progression-free survival with the combination of pemetrexed/bevacizumab compared with bevacizumab alone as maintenance therapy for advanced non- small-cell lung cancer, but the clinically relevant endpoint remains overall survival.By Howard (Jack) West.
 
Dr. Eric Topol talks with Dr. Napoleone Ferrara, recent winner of the Breakthrough Prize in Life Sciences and the researcher whose work led to the synthesis of bevacizumab and ranibizumab.
 
Speed
Series preference
1x
1x
Volume
100%
/

Google login Twitter login Classic login